Adaptimmune Therapeutics Earlier Reported Q2 EPS $(0.05) Beats $(0.25) Estimate, Sales $5.54M Miss $6.00M Estimate
Adaptimmune Therapeutics Earlier Reported Q2 EPS $(0.05) Beats $(0.25) Estimate, Sales $5.54M Miss $6.00M Estimate
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.25) by 80 percent. This is a 79.17 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $5.54 million which missed the analyst consensus estimate of $6.00 million by 7.70 percent. This is a 78.93 percent increase over sales of $3.10 million the same period last year.
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.25) by 80 percent. This is a 79.17 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $5.54 million which missed the analyst consensus estimate of $6.00 million by 7.70 percent. This is a 78.93 percent increase over sales of $3.10 million the same period last year.
自适应免疫治疗公司(纳斯达克市场代码:ADAP)公布季度亏损为每股0.05美元,比分析师普遍预期的0.25美元高出80%。这比去年同期每股亏损0.24美元增加了79.17%。该公司公布的季度销售额为554万美元,低于分析师一致预期的600万美元,降幅为7.70%。这比去年同期310万美元的销售额增长了78.93%。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧